CSL Limited: Hemophilia A trials

The registry lists 21 Hemophilia A studies with CSL Limited as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 1 3Phase 2 7Phase 3 11Phase 4 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B PatientsCompletedNCT03569891Phase 3Results posted
• Dose Confirmation Trial of AAV5-hFIXco-PaduaCompletedNCT03489291Phase 2Results posted
• Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia BCompletedNCT02396342Phase 1/2Results posted
• An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia ACompletedNCT02172950Phase 3Results posted
• Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia ACompletedNCT02093897Phase 3Results posted
• A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia BCompletedNCT02053792Phase 3Results posted
• A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia BCompletedNCT01662531Phase 3Results posted
• A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia BCompletedNCT01496274Phase 2/3Results posted
• An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia ACompletedNCT01486927Phase 2/3Results posted
• A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia BCompletedNCT01361126Phase 1/2Results posted
• Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCompletedNCT06738485Phase 3
• Observatory of Patients With Haemophilia B Treated by IdElvion®Active, not recruitingNCT05086575
• Register of Patients With haEmophilia A tReated With Afstyla®CompletedNCT04675541
• Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With InhibitorsTerminatedNCT02484638Phase 2/3
• Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody DevelopmentTerminatedNCT01445197Phase 3
• Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia BCompletedNCT01233440Phase 1
• Study of Biostate® in Children With Hemophilia ACompletedNCT01229007Phase 3
• Quality of Life Study of Helixate NexGenCompletedNCT01053715
• Health Related Quality of Life of Youth and Young Adults With Hemophilia ACompletedNCT01034904
• Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia ACompletedNCT00879541Phase 2
• Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)CompletedNCT00168090Phase 4